The influenza vaccine is given to protect against influenza in children older than six months of age and adults. The World Health Organization monitors influenza illness throughout the year and make recommendations on which three influenza types are likely to cause the most illness in the northern and in the southern hemisphere during their respective influenza seasons. Vaccine ingredients are specific to the brand of influenza vaccine they are associated with and may vary to year. Specific information on ingredients in the vaccines use each season can be found on the individual vaccine datasheets.
ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.
The annual influenza vaccine is now recommended for infants from six months of age, children and adults with certain chronic medical conditions that increase their risk of getting influenza or increase their risk of developing complications from influenza. Chronic conditions eligible for funded influenza vaccines include diabetes, heart, lung or kidney disease, asthma requiring regular preventer medication, cancer and conditions that suppress the immune system. The influenza vaccine is recommended and available free of charge for pregnant women and those aged 65 or over.
Children less than five years of age with certain medical conditions that increase their risk of invasive pneumococcal disease are eligible to start immunisations under the High Risk Pneumococcal Immunisation Programme.
Children less than 16 years of age with functional asplenia or who are pre or post splenectomy and those aged 16 years and over are eligible for immunisations under the Pre/Post Splenectomy Immunisation Programme.